Answers are grounded in this paper and cite their sources.
This article explores a novel AI-driven drug discovery model that automates development processes, suggesting new approaches in pharmaceutical research.
The convergence of generative artificial intelligence (AI) platforms and automated laboratory systems is ushering in a new era of drug discovery, in which a plain-language prompt can initiate a fully autonomous, end-to-end drug development program. This article explores the recent evolution of AI technologies and presents a “prompt-to-drug” pipeline, where AI not only generates novel hypotheses and designs optimized drug candidates but also orchestrates synthesis, validation, and clinical planning in a closed-loop system. By highlighting key breakthroughs, case studies, and the technological infrastructure required for this paradigm shift, we outline a vision for scalable, efficient, and unbiased drug discovery.
No takes yet. Share an insight, caveat, or question.
Zhavoronkov et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: